NCT03455309View on ClinicalTrials.gov

Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization

PHASE2CompletedINTERVENTIONAL
Enrollment

382

Participants

Timeline

Start Date

January 30, 2018

Primary Completion Date

July 19, 2019

Study Completion Date

October 15, 2019

Conditions
Staphylococcus Aureus
Interventions
BIOLOGICAL

NDV-3A

Single dose administered by intramuscular injection

BIOLOGICAL

Placebo

Single dose administered by intramuscular injection

Trial Locations (1)

31905

Fort Benning, Fort Benning

Sponsors
All Listed Sponsors
collaborator

Infectious Diseases Clinical Research Program

OTHER

collaborator

Uniformed Services University of the Health Sciences

FED

lead

NovaDigm Therapeutics, Inc.

INDUSTRY

NCT03455309 - Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization | Biotech Hunter | Biotech Hunter